REGN SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Oct 30, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Jul 30, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Apr 29, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Feb 4, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Oct 28, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 1, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Regeneron Reports Third Quarter 2026 Financial and Operating Results

Oct 30, 2026

8-K

Regeneron and Sanofi Enter Sixth Amendment to Collaboration Agreement for Four New Long-Acting Antibodies

Oct 6, 2026

8-K

Regeneron Details 2026 PSU Terms and Award Rationale for CEO and CSO

Sep 30, 2026

8-K

Regeneron Reports Strong Second Quarter 2026 Financial Results with Double-Digit Growth

Jul 30, 2026

8-K

Regeneron Pharmaceuticals Announces Expected Q2 2026 Acquired IPR&D Charge

Jul 6, 2026

8-K

Regeneron Pharmaceuticals, Inc. Announces Results of 2026 Annual Meeting of Shareholders

Jun 17, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

Common Stock and Class A Stock

Aug 10, 2020

424B3

Common Stock and Class A Stock

Aug 7, 2020

424B3

11,831,496 Shares

May 28, 2020

424B3

12,771,033 Shares

May 26, 2020

424B5

5,500,000 Shares

Oct 8, 2010

424B5

4,500,000 Shares

Oct 7, 2010

Registrations

TYPE

HEADLINE

FILED AT

S-3ASR

SHELF

Oct 31, 2024

SC TO-T/A

Registration

Sep 25, 2023

SC TO-T/A

Registration

Sep 12, 2023

SC TO-T/A

Registration

Sep 8, 2023

SC TO-T

Registration

Aug 25, 2023

SC TO-C

Registration

Aug 9, 2023

Proxies

TYPE

HEADLINE

FILED AT

N-PX

Form N-PX - Annual Report of proxy voting record of management investment companies

Aug 20, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 24, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 24, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 29, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 29, 2025

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Apr 7, 2025

Ownerships

TYPE

HEADLINE

FILED AT

Pitofsky Jason (Reporting)

Nov 6, 2026

MURPHY ANDREW J (Reporting)

Nov 5, 2026

13F-HR

Form 13F-HR - Quarterly report filed by institutional managers, Holdings

Nov 5, 2026

Zoghbi Huda Y (Reporting)

Nov 5, 2026

144

Form 144 - Report of proposed sale of securities

Nov 4, 2026

SING GEORGE L (Reporting)

Nov 4, 2026

Other

TYPE

HEADLINE

FILED AT

LETTER

Form UPLOAD - SEC-generated letter

Apr 17, 2025

CORRESP

Form CORRESP - Correspondence

Apr 3, 2025

LETTER

Form UPLOAD - SEC-generated letter

Mar 21, 2025

LETTER

Form UPLOAD - SEC-generated letter

Sep 11, 2024

CORRESP

Form CORRESP - Correspondence

Aug 1, 2024

LETTER

Form UPLOAD - SEC-generated letter

Jul 22, 2024

Regeneron Pharmaceuticals, Inc. REGN · SEC Filings